118 related articles for article (PubMed ID: 21868263)
1. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
de Martino M; Gigante M; Cormio L; Prattichizzo C; Cavalcanti E; Gigante M; Ariano V; Netti GS; Montemurno E; Mancini V; Battaglia M; Gesualdo L; Carrieri G; Ranieri E
Urol Oncol; 2013 Aug; 31(6):930-7. PubMed ID: 21868263
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
3. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
5. JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma.
Liang F; Liang H; Li Z; Huang P
Int Immunopharmacol; 2020 Sep; 86():106706. PubMed ID: 32570038
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
[TBL] [Abstract][Full Text] [Related]
7. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
[TBL] [Abstract][Full Text] [Related]
8. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
9. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
10. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
[TBL] [Abstract][Full Text] [Related]
11. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
Ma X; Yang K; Lindblad P; Egevad L; Hemminki K
Oncogene; 2001 Aug; 20(38):5393-400. PubMed ID: 11536052
[TBL] [Abstract][Full Text] [Related]
12. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
[TBL] [Abstract][Full Text] [Related]
13. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.
Gatalica Z; Lilleberg SL; Monzon FA; Koul MS; Bridge JA; Knezetic J; Legendre B; Sharma P; McCue PA
Hum Pathol; 2011 Dec; 42(12):1979-88. PubMed ID: 21733559
[TBL] [Abstract][Full Text] [Related]
14. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
16. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
[TBL] [Abstract][Full Text] [Related]
17. A germline mutation in PBRM1 predisposes to renal cell carcinoma.
Benusiglio PR; Couvé S; Gilbert-Dussardier B; Deveaux S; Le Jeune H; Da Costa M; Fromont G; Memeteau F; Yacoub M; Coupier I; Leroux D; Méjean A; Escudier B; Giraud S; Gimenez-Roqueplo AP; Blondel C; Frouin E; Teh BT; Ferlicot S; Bressac-de Paillerets B; Richard S; Gad S
J Med Genet; 2015 Jun; 52(6):426-30. PubMed ID: 25911086
[TBL] [Abstract][Full Text] [Related]
18. PPARγ is functionally expressed in clear cell renal cell carcinoma.
Collet N; Théoleyre S; Rageul J; Mottier S; Jouan F; Rioux-Leclercq N; Fergelot P; Patard JJ; Masson D; Denis MG
Int J Oncol; 2011 Mar; 38(3):851-7. PubMed ID: 21206970
[TBL] [Abstract][Full Text] [Related]
19. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
20. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]